Objective: To assess the efficacy and toxicity of decitabine-based conditioning regimen in patients with myelodysplastic syndrome (MDS) , acute myeloid leukemia secondary to MDS (MDS-AML) or chronic myelomonocytic leukemia (CMML) . Methods: From March 1, 2013 to May 25, 2015, 22 patients who underwent allogenic hematopoietic stem cell transplantation (allo-HSCT) with decitabine-based conditioning regimen were analyzed retrospectively. Results: ①22 patients, 14 males and 8 females with a median age of 42.5 (24-56) years old, were diagnosed as MDS (n=14) , CMML (n=4) , MDS-AML (n=4) . ②15 patients were treated with the conditioning regimen of decitabine combined with busulfan, cyclophosphamide, fludarabine, and cytarabine, the other 7 cases were treated with decitabine, busulfan, fludarabine, and cytarabine. The dose of decitabine was 20 mg·m(-2)·d(-1) for 5 days.Rabbit anti-human anti-thymocyte globulin (2.5 mg·kg(-1)·d(-1) for 4 days) was involved in conditioning regimen in patients with unrelated donor or haploidentical transplantation. ③Except 1 patient died of infection in 2 months after transplantation, the other patients were engrafted successfully. The median time of granulocyte engraftment was 13 (12-18) days, and the median time of platelet engraftment was 16 (13-81) days. ④The incidence of acute graft versus host disease (aGVHD) was (41.3±10.6) %, and severe aGVHD (grade of III-IV) was (18.4±9.7) %. The incidence of chronic graft versus host disease (cGVHD) was (56.4±11.3) %, and extensive cGVHD was (36.4±12.1) %. ⑤8 patients were suffered with cytomegalovirus (CMV) viremia. Among the 18 patients with definitely infection, 6 occurred during myelosuppression and 12 cases occurred after hematopoietic reconstruction. The 2-year and 3-year non-relapse mortality was (13.9±7.4) % and (24.3±9.5) %, respectively. ⑥The 2-year and 3-year overall survival (OS) was (77.3±8.9) % and (67.9±10.0) %, respectively. The 2-year and 3-year relapse-free survival (RFS) was (72.7±9.5) % and (63.6±10.3) %, respectively. Conclusions: allo-HSCT with decitabine-based conditioning regimen is feasible in the treatment of MDS, MDS-AML or CMML.
目的： 探讨含地西他滨预处理方案异基因造血干细胞移植（allo-HSCT）治疗骨髓增生异常综合征（MDS）、MDS转变急性髓系白血病（MDS-AML）及慢性粒-单核细胞白血病（CMML）的疗效及安全性。 方法： 回顾性分析2013年3月1日至2015年5月25日接受包含地西他滨预处理allo-HSCT治疗的22例MDS、CMML、MDS-AML患者的临床资料。 结果： ①全部22例患者中男14例、女8例，中位年龄42.5（24~56）岁；MDS 14例，CMML、MDS-AML各4例。②15例采用地西他滨（20 mg·m(-2)·d(-1)× 5 d）+白消安+环磷酰胺+氟达拉滨+阿糖胞苷预处理方案，7例采用地西他滨+白消安+氟达拉滨+阿糖胞苷预处理方案。无关供者移植、单倍型移植预处理加用兔抗人胸腺细胞免疫球蛋白（ATG）2.5 mg·kg(-1)·d(-1)×4 d。③22例（100%）患者均获得粒细胞植入，中位植入时间为13（12~18）d；21例（95.5%）患者获得血小板植入，中位植入时间为16（13~81）d。④急性GVHD、Ⅲ/Ⅳ度急性GVHD发生率分别为（41.3±10.6）%、（18.4±9.7）%；慢性GVHD、广泛型慢性GVHD发生率分别为（56.4±11.3）%、（36.4±12.1）%。⑤8例发生巨细胞病毒（CMV）血症；18例发生感染，其中6例发生于骨髓抑制期，12例发生于造血重建后；2年、3年非复发死亡率分别为（13.9±7.4）%、（24.3±9.5）%。⑥随访至2018年3月31日，14例患者存活，2年、3年总生存率分别为（77.3±8.9）%、（67.9±10.0）%；2年、3年无复发生存率分别为（72.7±9.5）%、（63.6±10.3）%。 结论： 对于MDS、CMML和MDS-AML患者而言，包含地西他滨预处理allo-HSCT是一种安全可行的治疗方法。.
Keywords: Chronic; Conditioning regimen; Decitabine; Myelodysplastic syndrome.